European equities traded in the US as American depositary receipts were edging lower Tuesday morning, declining 0.14% to 1,308.28 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by biotech firm BioNTech (BNTX) and internet advertising company Criteo (CRTO), which rose 5% and 4.6% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company DBV Technologies (DBVT), which were up 3.4% each.
The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biopharmaceutical company Grifols (GRFS), which fell 8.1% and 7.1% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and financial services company Banco Santander (SAN), which lost 3.1% and 2% respectively.
From the UK and Ireland, the gainers were led by biopharmaceutical companies Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP), which climbed 7.6% and 5.4% higher respectively. They were followed by biopharmaceutical company Amarin (AMRN) and utility company National Grid (NGG), which increased 3.2% and 0.9% respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Akari Therapeutics (AKTX), which tumbled 29.9% and 25.5% respectively. They were followed by insurance firm Prudential (PUK) and biopharmaceutical company Mereo BioPharma Group (MREO), which dropped 2.7% and 0.6% respectively.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。